Clinical Trial Update: Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating erlotinib hydrochloride in relapsed or refractory acute myeloid leukemia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
• Acute Myeloid Leukemia with Cbfb-myh11
• Acute Myeloid Leukemia with Inv Cbfb-myh11
• Acute Myeloid Leukemia with Mllt3-kmt2a
• Acute Myeloid Leukemia with Runx1-runx1t1
• Acute Promyelocytic Leukemia with Pml-rara
• Alkylating Agent-related Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia
• Previously Treated Myelodysplastic Syndrome

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 2 | Status: COMPLETED | Results posted: 2020-01-07